Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
There is increasing interest in the potential role of glucagon-like peptide-1 (GLP-1) receptor agonists as neuroprotective treatments in neurodegenerative diseases including Parkinson's disease following the publication of the results of the Exenatide-PD trial. Of the current GLP-1 receptor agonists already licensed to treat Type 2 diabetes several including exenatide, liraglutide and lixisenatide are the subject of ongoing clinical trials in PD. The underlying rationale for using drugs licensed and effective for T2DM in PD patients therefore needs to be scrutinized, and the results obtained to date critically reviewed. We review the relationship between insulin resistance and Parkinson's disease, the implications on pathogenesis and the efforts to reposition GLP-1 agonists as potential treatments for Parkinson's disease and give an overview of the pre-clinical and clinical data supporting the use of exenatide in Parkinson's disease with a discussion regarding possible mechanisms of action. This article is part of the Special Issue entitled 'Metabolic Impairment as Risk Factors for Neurodegenerative Disorders.'
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871 · cited 1×
“Stud ies in patients with AD have demonstrated that IRS-1 ph os orylated at serine residue positions 312, 616 or 636 in hippocampal tissues is associated with at tenuated insulin signaling and thus have been widely accepted as measures of neuronal insulin res stance (Moloney et al., 2010; Talbot et al., 2012; Yarchoan…”
Neuroinflammation and M2 Microglia: The Good, the Bad, and the Inflamed
Cherry, J. D., Olschowka, J. A., & O’Banion, M. K. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-98 · Cited by 1,748 · cited 1×
“As the resident immune cells of the CNS, microglia constantly survey the microenvironment an d can shift phenotype from a “quiescent” state to an “activated” state, leading to the secretion of a range inflammatory mediators, growth factors and cytokines that can either initiate/exacerbate oxida tive stress and trigger…”
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · cited 1×
“In view of differences regarding their pharmacodynamic and pharmacokinetic propertie s and efficacy in glycaemic control in diabetes (Bergenstal et al., 2010; Buse et al., 2009), it is reasonable to assume similar difference may exist in”
Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903 · cited 1×
“GLP-1 stimulation is known to increase intracellular cAMP (Drucker et al., 1987), while in creased cAMP expression upregulates the expression and activity of tyrosine hydroxylase (Ki m et al.”
Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889 · cited 4×
“The results of the 2 small trials provide hugely encouraging data that exenatide and/or other related drugs may eventually play a role in the treatment of Parkinson’s disease (Athauda et al., 2017b; Foltynie and Aviles-Olmos, 2014).”
InfluentialSelf-citationMitochondria in the aetiology and pathogenesis of Parkinson's disease
Schapira, A. H. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70327-7 · Cited by 883
Moloney, A. M., Griffin, R. J., Timmons, S., O’Connor, R., Ravid, R., & O’Neill, C. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.04.002 · Cited by 764 · cited 2×
“…demonstrated that IRS-1 phosphorylated at serine residue positions 312, 616 or 636 in hippocampal tissues is associated with attenuated insulin signaling and thus have been widely accepted as measures of neuronal insulin resistance (Moloney et al., 2010; Talbot et al., 2012; Yarchoan et al., 2014).”
Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589 · cited 1×
“M AN US CR IP T AC CE PT ED ACCEPTED MANUSCRIPT open-field activity, and rotarod (Li et al., 2009), while a separate study showed MPTP-treated rodents had increases in Mac1 and MMP-3 (markers of microgl ia activation) and elevated levels of proinflammatory cytokines TNFα and IL-1β (Kim et al.”
Hunter, K., & Hölscher, C. (2012) · BMC Neuroscience · doi:10.1186/1471-2202-13-33 · Cited by 504 · cited 2×
“Alt hough exenatide, liraglutide and lixisenatide have ll been shown to cross the blood-brain-barrier in rode nts (Hunter and Hölscher, 2012; Kastin and Akerstrom, 2003), there are apparent marked differe nces in the ratio of CSF:serum concentrations in humans; exenatide 2.”
Cited by
Kopp, K. O., Glotfelty, E. J., Li, Y., & Greig, N. H. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106550 · Cited by 298
Reich, N., & Hölscher, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.970925 · Cited by 248
Diet in Parkinson’s Disease: Critical Role for the Microbiome
Jackson, A., Forsyth, C. B., Shaikh, M., Voigt, R. M., Engen, P. A., Ramirez, V., & Keshavarzian, A. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01245 · Cited by 145
“Importantly, recent clinical trials show that GLP-1 agonists elicit significant improvements in PD patient disease scores compared to placebo (248, 257, 258).”
BackgroundIncretin and insulin signaling as novel therapeutic targets for Alzheimer’s and Parkinson’s disease
Nowell, J., Blunt, E., & Edison, P. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01792-4 · Cited by 136
Chiappini, S., Vickers-Smith, R., Harris, D., Papanti Pelletier, G. D., Corkery, J. M., Guirguis, A., Martinotti, G., Sensi, S. L., & Schifano, F. (2023) · Pharmaceuticals · doi:10.3390/ph16070994 · Cited by 78
Metadata
- Authors
- Athauda, D., & Foltynie, T.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 136
- Issue
- Pt B
- Pages
- 260-270
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W2756066122
- Cited by
- 98
- References
- 32
- FWCI
- 5.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease. https://app.cochat.ai/papers/10.1016/j.neuropharm.2017.09.023
- The paper
- Athauda, D., & Foltynie, T. (2018). Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2017.09.023
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.